Articles tagged with Vaccine Target
Researchers found that antibodies against one of the two main domains of the SARS-CoV-2 viral entry machinery elicit a broad antibody response against many variants. This suggests strategies for clinical development of variant-resistant vaccines.
A team from UNIGE has revealed the existence of a hidden 'pocket' on the surface of the non-structural protein Nsp1, which could be used to develop new treatments against Covid-19. This discovery paves the way for innovative therapies targeting the Nsp1 protein and its potential application against other coronaviruses.
Researchers found that IV administration of the experimental cancer vaccine, SNAPvax, boosted cytotoxic T cells capable of infiltrating tumor cells and engaged the innate immune system. This approach overcomes tumor-induced immunosuppressive activity, enabling enhanced T-cell immunity.
Researchers from McGill University found that pneumococcal vaccination uptake is low among adults at high risk in Canada. Despite the importance of pneumococcal vaccination to prevent pneumonia and other forms of pneumococcal disease, many people missed opportunities for vaccination.
A recent analysis of COVID-19-positive donor heart transplants found no significant differences in transplant outcomes compared to those from non-COVID-19 donors. The study's results suggest that COVID-19-positive hearts may be as safe for transplantation, potentially addressing the shortage of available donor organs.
A new study led by Duke-NUS Medical School scientists found that inactivated SARS-CoV-2 vaccines elicit a broad immune response against different proteins on the virus, while mRNA vaccines stimulate a single spike protein response. This broader T-cell response may be beneficial in preventing severe COVID-19 disease.
A recent study by West Virginia University sociologists found that individuals with paranormal beliefs are more likely to be hesitant about vaccination. These beliefs, which include astrology and spirits, lead to a lack of confidence in science and vaccines, including the COVID-19 shot.
Researchers at the University of Illinois College of Veterinary Medicine have identified a specific type of T cell that produces cytokines necessary for acquiring immunity against fungal pathogens. This finding could lead to the development of effective fungal vaccines.
Researchers have mapped the critical protein structure of the Hepatitis C virus, revealing key sites of vulnerability that can be targeted with vaccines. The discovery could lead to an effective HCV vaccine, which would eliminate the virus as a public health burden.
A novel COVID-19 vaccine developed by Brazilian scientists combines two SARS-CoV-2 proteins to trigger a cellular immune response. The vaccine, called SpiN, showed promise in animal trials, protecting against three strains of the virus and reducing viral load by up to 50 times.
Researchers develop custom vaccines that induce broadly neutralizing antibodies to protect against HIV variants. The team uses a modified HIV spike protein to prime the immune system, paving the way for an effective HIV vaccine.
Researchers developed a faster, more affordable method to analyze serological data and predict COVID-19 wave behavior. The study showed that vaccination boosted immunity, with hybrid immunity producing higher protection levels. Antibody levels rose quickly after the first dose, especially in cities where case numbers were highest.
Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.
A data-intelligent model reveals that prioritizing vaccine access for the most disadvantaged communities can improve health benefits for all. The research team also argues for increased funding to combat vaccine hesitancy among these populations.
Researchers have identified two effective antibodies that neutralize all known strains of COVID-19, including Delta and Omicron variants. These breakthrough antibodies could eliminate the need for repeated booster vaccinations and strengthen immune systems, especially in at-risk populations.
A new Israeli study found that myocarditis cases were rare and mild after the third dose of Pfizer-BioNTech COVID-19 vaccine, with a risk of 1 in 15,000 among young males. The study's findings suggest potential explanations for the increased risk, including medical precautions and time between doses.
Public health researchers developed a global vaccine risk index (VRI) to predict vaccine coverage lapses worldwide. The VRI considers factors like measles incidence, vaccine confidence, climate change, education, and income, revealing countries at high risk of disease outbreaks.
A recent study found that COVID-19 infection significantly increases the risk of myocarditis compared to vaccination, with a 11-fold higher risk in unvaccinated individuals. The study analyzed nearly 43 million people in England and found that COVID-19 vaccine-associated myocarditis is rare.
A survey study of 135,000 adults found that less than half had received a booster dose, with marked variations across regions and sociodemographic groups. Targeted efforts may be needed to improve booster vaccine coverage in these populations.
A quality improvement program increased pneumococcal vaccination rates from 53% to 70% in adults aged 18-64 years with stage 4 and 5 chronic kidney disease. The intervention, which utilized electronic best practice alerts within the electronic medical record, improved vaccination rates primarily among this high-risk group.
A genomic surveillance study has identified a 'shapeshifting' strain, GPSC10, which is resistant to multiple antibiotics and can express 17 different serotypes. This study highlights the importance of genomic surveillance in informing vaccine design and tracking the emergence of new strains.
Scientists at Scripps Research have identified antibodies that induce broad immunity against SARS viruses, including emerging variants. The discovery reveals the antibody structures that produce this more comprehensive immune response and could inform the development of next-generation vaccines.
Researchers at the Francis Crick Institute have made significant progress in designing a pan-coronavirus vaccine that targets the S2 area of the spike protein, offering protection against multiple coronaviruses and potential future pandemics. The study found that antibodies targeting this area can neutralize a range of coronaviruses, i...
Researchers found that mothers who didn't transmit HCMV to their infants had higher levels of antibody-dependent cellular phagocytosis, suggesting a non-neutralizing immunity mechanism. This finding has implications for the development of effective HCMV vaccines.
Researchers have developed a novel COVID-19 vaccine based on altered plasmid DNA that effectively blocks cell infection across all tested variants. The vaccine targets a specific vulnerability in the SARS-CoV-2 virus's spike protein, inducing a focused antibody response.
Researchers developed a mathematical model to predict the efficiency of nanoparticle delivery into cells, particularly in stem cells. They found that nanoparticles become trapped in bubble-like vesicles, preventing them from reaching their targets.
MU researchers have identified specific mutations in the Omicron variant's spike protein that help it evade existing antibodies from vaccines or previous COVID-19 infections. These findings can inform developers of COVID-19 treatments and vaccines, which may need to target different parts of the virus to produce effective outcomes.
The SARS-Arena program identifies conserved peptides in the SARS-CoV-2 virus that could be used to develop vaccines. The peptides are part of the nucleocapsid protein, which is highly expressed upon infection and highly immunogenic.
A new study found that the fourth COVID-19 vaccine reduces the risk of death among elderly individuals in long-term care facilities by 72%. The study, which included approximately 40,000 residents, also showed a significant reduction in hospitalizations and infections.
Scientists have found that prior exposure to Staphylococcus aureus prevents effective vaccination due to immune response memory. To overcome this, the research suggests targeting only the protective component of the protein IsdB, generating a more effective vaccine against MRSA.
A new study found that COVID-19 vaccine acceptance increased 3.7% worldwide between 2020 and 2021, with concerns about vaccine safety and efficacy being the primary drivers of hesitancy. The study also revealed that vaccine mandates were strongly supported among international travelers but had lower support among schoolchildren.
Researchers analyzed antibodies to internal and surface proteins of SARS-CoV-2, finding that profiles of internal proteins predicted survival outcomes as well as those for surface proteins. The study suggests targeting other parts of the virus could enhance COVID-19 vaccines and therapies.
A mathematical modelling study published in The Lancet Infectious Diseases estimates that COVID-19 vaccines have prevented approximately 19.8 million deaths worldwide in the first year of the vaccination program, a reduction of 63%. This represents nearly 80% of potential deaths that would have occurred without vaccination.
Scientists have discovered a new, high-resolution view of the rabies virus glycoprotein, which could lead to more effective vaccines. The study's findings suggest that a better-shaped vaccine could provide lifelong protection against the deadly disease.
A molecule in mosquito spit called sialokinin has been identified as a potential new target for vaccination against Yellow Fever, Dengue and Zika. Researchers found that sialokinin causes blood vessels to become permeable, allowing viruses to infect the host.
A study analyzing 17 million patient GP records in England found that people with certain inflammatory immune conditions were at higher risk of dying or needing hospital care from COVID-19. The analysis suggests that targeting prevention strategies and early interventions towards those most at risk can help inform evidence-based policy.
Researchers at Karolinska Institutet have identified a new vaccine candidate based on nano-sized membrane vesicles that provide protection against multiple pneumococcal strains. The vaccine target two conserved lipoproteins MalX and PrsA, showing serotype-independent cross-protection.
A recent study at Cedars-Sinai Medical Center found that biologic drugs for inflammatory bowel disease may improve the T-cell immune response in patients vaccinated against COVID-19. This could potentially offer protection against severe disease. The study suggests that these treatments may be used to monitor vaccine and booster outcomes.
The UK's Joint Committee on Vaccination and Immunisation advises that COVID vaccines should be offered to 5–11-year-old children, but deem immunization as non-essential. Dr Hamid Merchant explains why current vaccines are not suitable for children due to efficacy and safety concerns.
A new analysis of nationally representative data reveals a significant increase in the impact of HPV vaccination efforts, leading to decreased prevalence of cancer-causing HPV infections among both vaccinated and unvaccinated females. The study found that vaccination has directly protected individuals and generated herd effects, reduci...
Researchers found that COPD leads to premature senescence of the immune system, reducing CD4+ and CD8+ T cells. This disruption impairs the immune system, making COPD patients more susceptible to infections.
Researchers have identified helpful and unhelpful aspects of the immune response that determine whether TB infections can be kept under control. The findings may help design a more effective vaccine by targeting specific cell subsets and modulating intercellular signaling.
A new study by CUNY SPH researchers found that nearly 40% of NYC parents are hesitant to vaccinate their young children against COVID-19, with many citing safety concerns. The study suggests that mandates may be key in increasing vaccine coverage among children.
Researchers found that left-handed chiral gold nanoparticles increased the immune response in human cells even without an antigen, leading to a 25.8% increase in vaccine efficacy. The discovery uses chirality to enhance immune responses, potentially applicable to various vaccines.
This analysis examines the association between COVID-19 vaccination prioritization policies and incarcerated individual vaccination rates. The study found that policies favoring certain groups led to significantly lower vaccination rates among incarcerated populations.
The University of Missouri has received a grant to help nurses discuss COVID-19 vaccination hesitancy with their communities. The project will equip nursing students with knowledge and confidence to promote public health through effective communication strategies.
A new CAR T-cell product targeting CLDN6 showed acceptable safety and early signs of efficacy in a phase I/II clinical trial. The therapy combined with an mRNA vaccine expanded transferred CAR T cells and improved tumor cell killing.
Researchers at Temple University found that individuals with prior COVID-19 infection experienced rapid antibody production after the first vaccine dose, but showed little increase after the second dose. This contrasts with those without a history of infection, who exhibited massive responses after the second dose.
A new vaccine platform, using spherical nucleic acid (SNA) nanoparticles, has been shown to produce an immune response in animals and offer protection against lethal doses of the SARS-CoV-2 virus. The results suggest that this approach could be used to target other infectious diseases.
A study found that maternal immunization against respiratory syncytial virus (RSV) can reduce antimicrobial prescribing among young infants. The research, based on a blinded, multi-country trial, showed that infants of mothers assigned the RSV F vaccine experienced fewer antimicrobial prescription courses over the first 90 days of life.
A new study suggests that maintaining face mask use for two to 10 weeks beyond reaching vaccination coverage thresholds of 70-90% fully vaccinated could prevent a substantial number of cases, hospitalizations, and deaths, while saving businesses and taxpayers money. The study found that this could save $2.9 billion in direct medical co...
The Oxford-AstraZeneca vaccine demonstrated 31% protection against symptomatic COVID-19 after one dose and 65% after the second dose in a Brazilian favela community. The study aimed to assess vaccine effectiveness in socially vulnerable populations, which have been disproportionately affected by the pandemic.
A Brazilian study of 2,777 patients hospitalized between January 5 and September 12, 2021 found that vaccination was the sole predictor of mortality in those over 60 with kidney failure. Vaccination also reduced hospitalization risk among non-vaccinated patients with comorbidities.
A University of Ottawa group is conducting research to equip healthcare professionals with resources to aid patients in French-speaking minority settings make informed decisions about COVID-19 vaccines. The project aims to address language barriers and combat patient disinformation.
A study found that COVID-19 patients from high-vulnerability neighborhoods presented with more severe illness and required intensive care, but did not experience higher mortality rates. Researchers suggest policies targeting socially vulnerable neighborhoods to improve access to testing, treatment, and vaccination.
Researchers at Johns Hopkins Medicine discovered a peptide on the SARS-CoV-2 spike protein that triggers an immune response in humans and is also recognized by cells of the immune system, suggesting potential for protection against future zoonotic outbreaks. The study supports the development of multivalent vaccines against a broad spe...
Scientists at Scripps Research identified a common target on the spike protein of multiple coronaviruses, including SARS-CoV-2, that can be targeted by a broad-spectrum vaccine. The discovery could inform the design of effective vaccines and antibody therapies against future coronavirus pandemics.
The University of Texas at San Antonio has established a San Antonio-based Coccidioidomycosis Collaborative Research Center (SA-CCRC) focused on developing therapeutics and vaccines against coccidioidomycosis. The center will support applied clinical research and house an extended network of experts from partnering institutions.
Researchers attribute vaccine effectiveness to mutations shared with previous variants, resulting in relatively small severe cases and deaths among vaccinated patients. The study analyzed over 200,000 genomes and found identical mutations that could serve as targets for future vaccines.
A computational study finds that Omicron's spike protein has evolved to evade multiple classes of antibodies targeting SARS-CoV-2, even those from vaccinated individuals and monoclonal antibody treatments. The study suggests vaccines still offer protection due to the development of T cell immunity.